Exact Mass: 379.1242
Exact Mass Matches: 379.1242
Found 75 metabolites which its exact mass value is equals to given mass value 379.1242,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
2H-1-Benzopyran-2-one, 7-[[2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]oxy]-4-methyl-
Licofelone
D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D004791 - Enzyme Inhibitors > D016859 - Lipoxygenase Inhibitors D002491 - Central Nervous System Agents > D000700 - Analgesics C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor D000893 - Anti-Inflammatory Agents Licofelone (ML-3000) is a dual COX/5-lipoxygenase (5-LOX) inhibitor (IC50=0.21/0.18 μM, respectively) for the treatment of osteoarthritis. Licofelone exerts anti-inflammatory and anti-proliferative effects. Licofelone induces apoptosis, and decreases the production of proinflammatory leukotrienes and prostaglandins[1][2][3].
Cyclohexanecarboxamide, N-(2-((ethylsulfonyl)amino)-5-(trifluoromethyl)-3-pyridinyl)-
Licofelone
D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D004791 - Enzyme Inhibitors > D016859 - Lipoxygenase Inhibitors D002491 - Central Nervous System Agents > D000700 - Analgesics C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor D000893 - Anti-Inflammatory Agents Licofelone (ML-3000) is a dual COX/5-lipoxygenase (5-LOX) inhibitor (IC50=0.21/0.18 μM, respectively) for the treatment of osteoarthritis. Licofelone exerts anti-inflammatory and anti-proliferative effects. Licofelone induces apoptosis, and decreases the production of proinflammatory leukotrienes and prostaglandins[1][2][3].
C24H17N3O2_(7Z)-7-Benzylidene-6-methyl-6,7-dihydroquinazolino[3,2-a][1,4]benzodiazepine-5,13-dione
Hymecromone, O-(2-Acetamido-2-deoxy-beta-D-glucopyranoside)
Coumarins
Cys Gly Asn Ser
Cys Gly Ser Asn
Cys Asn Gly Ser
Cys Asn Ser Gly
Cys Ser Gly Asn
Cys Ser Asn Gly
Gly Cys Asn Ser
Gly Cys Ser Asn
Gly Asn Cys Ser
Gly Asn Ser Cys
Gly Ser Cys Asn
Gly Ser Asn Cys
Asn Cys Gly Ser
Asn Cys Ser Gly
Asn Gly Cys Ser
Asn Gly Ser Cys
Asn Ser Cys Gly
Asn Ser Gly Cys
Ser Cys Gly Asn
Ser Cys Asn Gly
Ser Gly Cys Asn
Ser Gly Asn Cys
Ser Asn Cys Gly
Ser Asn Gly Cys
7-FLUORO-3,4-DIHYDRO-4-[(5-ISOQUINOLINYLOXY)ACETYL]-3,3-DIMETHYL-2(1H)-QUINOXALINONE
Urea, N-(4-chlorophenyl)-N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]- (9CI)
Urea, N-(2-chlorophenyl)-N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]- (9CI)
Urea, N-(2-chlorophenyl)-N-[2-[(3-cyano-6-methyl-2-quinolinyl)amino]ethyl]- (9CI)
4-methylumbelliferyl-2-acetamido-2-deoxy-alpha-d-glucopyranoside
METHYL 4-(((BENZYLOXY)CARBONYL)AMINO)-2-FLUORO-[1,1-BIPHENYL]-3-CARBOXYLATE
METHYL 4-(((BENZYLOXY)CARBONYL)AMINO)-6-FLUORO-[1,1-BIPHENYL]-3-CARBOXYLATE
4-Methylumbelliferyl-N-acetyl-beta-D-galactosaminide hydrate
6-Oxo-2-phenyl-5-[[(phenylmethoxy)carbonyl]amino]-1(6H)-pyrimidineacetic acid
4,11-diamino-2-(3-methoxypropyl)-1H-Naphth[2,3-f]isoindole-1,3,5,10(2H)-tetrone
2-[4-[2-[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]vinyl]phenyl]benzoxazole
(4-N-(Benzhydryloxycarbonyl)cytosine)-1-acetic acid
(3-Chloro-5-trifluoroMethyl-3,4,5,6-tetrahydro-2H-[1,2]bipyridinyl-3-yl)-carbaMic acid tert-butyl ester
4-Methylumbelliferyl 2-amino-2-deoxy-a-D-glucopyranoside
5-(3-((2S)-(1,4-Benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxol hydrochloride
Fuzapladib
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C2144 - Endothelial-Specific Integrin/Survival Signaling Inhibitor D004791 - Enzyme Inhibitors > D064801 - Phospholipase A2 Inhibitors C308 - Immunotherapeutic Agent > C574 - Immunosuppressant Fuzapladib (IS-741), an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site[1][2].
N2,N2-dimethyl-6-[[[1-(1-naphthalenyl)-5-tetrazolyl]thio]methyl]-1,3,5-triazine-2,4-diamine
3-[Isopropyl(4-methylbenzoyl)amino]-5-phenylthiophene-2-carboxylic acid
1-Benzimidazolyl-[2-(4-methoxyphenyl)-4-quinolinyl]methanone
N-[1-(2-chloro-6-fluorobenzyl)-4-piperidinyl]-N-(4-fluorophenyl)urea
N-(2-chloroethyl)-N-(6-chloro-2-methoxyacridin-9-yl)propane-1,3-bis(aminium)
2-methylthio-N(6)-(cis-4-hydroxy-Delta(2)-isopentenyl)adenosine residue
A nucleoside residue in which an adenosine residue has been modified by substitution at C-2 by a methylthio (methylsulfanyl) group and at the 6-amino nitrogen by a cis-4-hydroxy-Delta(2)-isopentenyl group.
